Eton Pharmaceuticals EV/EBIT ETON

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.

Today, Oct 23, 2026: n/m; a quarter missing
3-year median: 102×
3-year range: 39.2× to 497×
Peer median: 9.9×

Eton Pharmaceuticals' EV/EBIT can't be checked today: its operating income for Q2 FY26, the quarter to Jun 30, 2026, is missing from our data, so the twelve months it rests on can't be added up.

On the days it had one over the last 3 years, its median was 102×, from 39.2× in Nov 2023 to 497× in Jul 2026.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	87.7×	87.7×	497×
2025	n/m a value too high to mean anything
2024	148×	47.4×	150×
2023	50.7×	39.2×	53.6×

Against its peers

Companies in Drug Manufacturers - General nearest Eton Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
ETONEton Pharmaceuticals	n/m
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	11.7×
ANIPANI Pharmaceuticals	10.5×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	12.2×
HRMYHarmony Biosciences	6.9×
PBHPrestige Consumer Healthcare	14.5×
ABUSArbutus Biopharma	4.9×
COLLCollegium Pharmaceutical	9.4×
Peer median	9.9×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Eton Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.